Table 1.
Clinical characteristics of CML patients with common ACAs
| Parameters | Group 1 | Group 2 | ||||
|---|---|---|---|---|---|---|
| Trisomy 8 (n = 37) | −Y (n = 29) | Extra Ph (n = 35) | i(17)(q10) (n = 17) | −7/del(7q) (n = 14) | 3q26 (n = 23) | |
| Sex | ||||||
| Male | 19 (51%) | 29 (100%) | 25 (71%) | 11 (65%) | 11 (79%) | 17 (74%) |
| Female | 18 (49%) | 0 (0%) | 10 (29%) | 6 (35%) | 3 (21%) | 6 (26%) |
| Age (y) | ||||||
| Median | 44 | 59 | 49 | 47 | 58 | 47 |
| Range | 20-71 | 21-81 | 22-86 | 25-74 | 27-70 | 22-76 |
| Interval (mo) | ||||||
| Median | 23 | 3.5 | 33 | 30 | 11 | 13 |
| Range | 0-98 | 0-87 | 0-160 | 0-110 | 0-109 | 0-120 |
| Emerged from | ||||||
| CP | 33 (89%) | 29 (100%) | 26 (74%) | 10 (59%) | 4 (29%) | 12 (52%) |
| AP | 1 (3%) | 0 (0%) | 4 (12%) | 5 (29%) | 1 (7%) | 3 (13%) |
| BP | 3 (8%) | 0 (0%) | 5 (14%) | 2 (12%) | 9 (64%) | 8 (35%) |
| Emergence time | ||||||
| At CML diagnosis | 6 (16%) | 14 (48%) | 5 (14%) | 2 (12%) | 3 (21%) | 3 (13%) |
| During CML course | 31(84%) | 15 (52%) | 30 (86%) | 15 (88%) | 11 (79%) | 20 (87%) |
| TKI response | n = 22 | n = 26 | n = 19 | n = 15 | n = 4 | n = 19 |
| CCyR | 12 (55%) | 17 (65%) | 12 (63%) | 2 (13%) | 1 (25%) | 0 (0%) |
| MMR | 11 (50%) | 16 (62%) | 10 (53%) | 1 (7%) | 0 (0%) | 0 (0%) |
| F/U (mo) | ||||||
| Median | 49 | 69 | 23 | 34 | 10 | 15 |
| Range | 0.2-190 | 0.2-188 | 3.9-153 | 6.7-123 | 0.1-154 | 2-91 |
| Status at last F/U | ||||||
| Dead | 13 (35%) | 7 (24%) | 13 (37%) | 14 (82%) | 10 (71%) | 20 (87%) |
| Alive | 24 (65%) | 22 (76%) | 22 (63%) | 3 (18%) | 4 (29%) | 3 (13%) |
Age, age at initial CML diagnosis; F/U (mo), time from the emergence of ACAs to death or the last follow-up; interval (mo), time from CML diagnosis to ACAs emergence; TKI response, patients who received other concurrent therapies such as chemotherapy for BP, were excluded for TKI response analysis (in addition, patients who died or underwent stem cell transplant shortly after ACA emergence were also excluded for TKI response analysis).